There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA. The ...
Trailing total returns as of 2/10/2026, which may include dividends or other distributions. Benchmark is FTSE Bursa Malaysia KLCI (^KLSE) Return 8885.KL FTSE Bursa Malaysia KLCI (^KLSE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results